Immune Landscape with MBC
Researchers compared the immune microenvironments of primary tumors with those at sites of metastases.
Vinay Prasad papers on twitter
Tumour Mutational Burden
Recent Updates: Friends of Cancer Research recently hosted a TMB Harmonization Working Group Meeting on this topic on May 10, 2018. Friends also released a press release on September 18th, 2018 announcing the beginning of Phase 2 of the project.
Roche’s Tecentriq is on its way to becoming the first immuno-oncology drug with an approval in triple negative breast cancer, and that path just got shorter.
Screening for late stage cancers
Vitamin D and Fish Oil
The largest study to test vitamin D and omega-3 pills in healthy adults found they did little to prevent cardiovascular disease, but hinted at benefits for groups including African-Americans.
New Insights Into Mets
Fever After Zoledronic Acid
Bone Marrow Mets Protein
For the first time ever, Mount Sinai researchers have identified a protein as a marker that can indicate whether a cancer patient will develop a reoccurrence of lethal, metastatic cancer, according to a clinical study published in Breast Cancer Research in October.
Broadening Eligibility Criteria to Make Clinical Trials More Representative
Purpose The primary purposes of eligibility criteria are to protect the safety of trial participants and define the trial population. Excessive or overly restrictive eligibility criteria can slow trial accrual, jeopardize the generalizability of results, and limit understanding of the intervention’s benefit-risk profile. Methods ASCO, Friends of Cancer Research, and the US Food and Drug…
US Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer – Full Text View.
Novartis punts a late-stage PI3K drug with a worrying safety profile to one of China’s upstart biotechs
Just months after a group of researchers warned against the further development of a worrying PI3K inhibitor project Novartis had been working on, the pharma giant licensed out the global rights to a newly active Chinese biotech. Novartis is the latest in a long string of Big Pharma players who
Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials
PDF | We report the experience with 2,000 consecutive patients with advanced cancer who underwent testing on a genomic testing protocol, including the frequency of actionable alterations across tumor types, subsequent enrollment onto clinical trials, and the challenges for trial…
2018 07 Triple Negative Impassion130 Trial Phase 3
2018 06 Metastasis Protein Found
New data identifies AXL as a potential antimetastatic co-therapeutic target for the treatment of HER2+ breast cancers
The impact of circulating tumor cells (CTCs) detection in metastatic breast cancer (MBC): Implications of “indolent” stage IV disease (Stage IVindolent).
1019 The impact of circulating tumor cells (CTCs) detection in metastatic breast cancer (MBC): Implications of “indolent” stage IV disease (Stage IVindolent). Andrew A. Davis, Jean-Yves Pierga, Luc Yves Dirix, Stefan Michiels, Alfred Rademaker, James M. Reuben, Tanja N. Fehm, Elisabetta Munzone, Mario Giuliano, Jose Vidal-Martinez, Dimitrios Mavroudis, Salvatore Grisanti, Daniele Giulio Generali, Jose Angel…
Everolimus for Endocrine Resistence in BC
Everolimus proved to be effective tool for overcoming endocrine resistance in postmenopausal women with ER-positive, HER2-negative metastatic breast cancer that have become resistant to aromatase inhibitor therapy.
Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer
Proteomic mapping of dynamic changes in kinase signaling after drug treatment identifies that AURKA inhibition is required for drug sensitivity, representing a new co-targeting opportunity with PI3K, AKT, or mTOR inhibitors in breast cancer.
Dr. Stephanie Graf CDK4/6 Inhibitor advances
More transparency in reporting of harms in cancer drug trials
Studies of cancer drugs often use terms that downplay the seriousness of adverse events. Bishal Gyawali and colleagues call for greater clarity and transparency The clinical trial report of ribociclib, a drug for breast cancer, mentions in its discussion that “Most patients had an acceptable adverse-event profile.”1 A report of a trial of liposomal irinotecan…
Frequency and level of evidence, a retrospective observational study
Objective To determine the differences between recommendations by the National Comprehensive Cancer Network (NCNN) guidelines and Food and Drug Administration approvals of anticancer drugs, and the evidence cited by the NCCN to justify recommendations where differences exist. Design Retrospective observational study. Setting National Comprehensive Cancer Network and FDA. Participants 47 new molecular entities approved by…
Surrogate outcomes are not intrinsically beneficial to patients, but are designed to be easier and faster to measure than clinically meaningful outcomes. The use of surrogates as an endpoint in clinical trials and basis for regulatory approval is common, and frequently exceeds the guidance given by regulatory bodies. In this article, we demonstrate that the…